Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Gastric or GEJ Adenocarcinoma
NCT02589496Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Mar 2016
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Samsung Medical Center. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02589496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589496.